There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Titles as Introduced

Neuromyelitis Optica Consortium Act

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To amend the Public Health Service Act to create a National Neuromyelitis Optica Consortium to provide grants and coordinate research with respect to the causes of, and risk factors associated with, neuromyelitis optica, and for other purposes.


Actions Overview (1)

Date Actions Overview
01/05/2017Introduced in House

All Actions (3)

Date All Actions
01/25/2017Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
01/05/2017Referred to the House Committee on Energy and Commerce.
Action By: House of Representatives
01/05/2017Introduced in House
Action By: House of Representatives

Cosponsors (0)

No cosponsors.


Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Energy and Commerce01/05/2017 Referred to
House Energy and Commerce Subcommittee on Health01/25/2017 Referred to

No related bill information was received for H.R.326.


Latest Summary (1)

There is one summary for H.R.326. View summaries

Shown Here:
Introduced in House (01/05/2017)

Neuromyelitis Optica Consortium Act

This bill amends the Public Health Service Act to require the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis. The consortium must:

  • award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO;
  • assemble a panel of experts to provide guidance and recommendations on research design and protocols; and
  • designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.